Johnson & Johnson posts strong revenue in 1Q

Lower sales overseas and higher costs for research and litigation pushed Johnson & Johnson’s first-quarter profit down 14%. Still, the health care giant beat profit and revenue expectations, pushing up its shares in premarket trading.

The maker of Tylenol and psoriasis drug Stelara on Tuesday said unfavourable currency exchange rates reduced revenue by nearly 4%, leaving total sales flat at $20.03 billion, though that edged out analysts’ muted projections.

Sales of prescription medicines were the bright spot as usual, rising 4% and accounting for over half of the New Brunswick, New Jersey, company’s total revenue.

The segment just got a boost from two U.S. Food and Drug Administration approvals, in March for nasal spray treatment Spravato for adults with treatment-resistant depression and last week for bladder cancer drug Balversa.

Earlier this month, J&J completed a key acquisition, paying $3.4 billion for Auris Health, which makes robotic technology used in lung treatments and diagnostic procedures. Johnson & Johnson said the deal will expand its digital surgery portfolio across multiple surgical specialties. J&J also struck a partnership with MeiraGTx to develop gene therapies for eye diseases.

The world’s biggest maker of health care products posted net income of $3.75 billion, or $1.39 per share, down from $4.37 billion, or $1.60 per share, a year earlier.

Earnings, adjusted for litigation costs and research and development expenses, were $5.66 billion, or $2.10 per share, 7 cents better that Wall Street expected, according to a survey by Zacks Investment Research.

Revenue was $20.02 billion, with $10.24 billion of that coming from its prescription drugs. Sales were led by Stelara, which saw a 32.4% jump to $1.41 billion. Higher sales of cancer drugs Imbruvica and Darzalex, HIV drug Prezista and schizophrenia treatment Invega Sustenna also lifted the results and helped offset lower sales of blockbuster immune treatment Remicade and blood thinner Xarelto.

Sales of consumer health products dipped 2.4% to $3.32 billion, and medical device sales fell 4.6% to $6.46 billion.

The company reaffirmed its January forecast for 2019 sales totalling $80.4 billion to $81.2 billion, but raised the low end of its earnings-per-share forecast 3 cents, giving a new range of $8.53 to $8.63 for the full year.

In premarket trading, J&J shares jumped $2.57, or 1.9%, to $139.09.

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

Central Alberta school boards await funding details

Alberta Education announces new funding model

New Red Deer utility rates take effect March 1

The City of Red Deer has increased its utility fees. Beginning March… Continue reading

Trudeau says Wet’suwet’en crisis, rail blockades a critical moment for country

First Nations leaders suggest it may be time to peacefully end the blockades

Four people charged in drug trafficking investigation

Rocky Mountain House RCMP execute search warrant

Drive-by shooting in Wetaskiwin on Sunday

Two people injured in shooting

Your community calendar

Feb. 19 A Liberation of Holland event is being held at the… Continue reading

New highway to B.C. proposed

The Howse Pass shortcut to British Columbia is worth taking another look… Continue reading

Stolen car provides opportunity to try out public transit

I had my car stolen on Jan. 10, just as our one… Continue reading

‘Schitt’s Creek,’ ‘Anne with an E’ lead Canadian Screen Awards pack

TORONTO — It will be a celebrated ending for Schitt’s Creek and… Continue reading

Prison watchdog raises concerns of ‘culture of impunity’

OTTAWA — Canada’s prison watchdog is raising concerns about the safety, rights… Continue reading

Top earners pay more in B.C. budget that includes record capital spending

VICTORIA — Top income earners and pop drinkers were hit with new… Continue reading

N.L. Premier Dwight Ball denies he’s walking away as going gets tough

ST. JOHN’S, N.L. — As he prepares to step down as premier… Continue reading

County waiting on response to Buffalo Lake RV plan

The County of Stettler was expecting to receive a decision by last… Continue reading

Most Read